Target intelligence / Profile preview

DNAJC6 antisense RNA 1 (DNAJC6-AS1)

Target
DNAJC6-AS1
Molecular classification
Long noncoding RNA (lncRNA), Antisense RNA, Noncoding RNA
01

Overview

DNAJC6 antisense RNA 1 (DNAJC6-AS1) is a putative long noncoding RNA transcript antisense to the DNAJC6 locus. While antisense RNAs in general are implicated in diverse gene regulatory processes, there is currently no specific experimental evidence for the biological function, disease association, or therapeutic targeting of DNAJC6-AS1 in humans. The protein-coding DNAJC6 gene (Auxilin) is important for synaptic vesicle endocytosis and is associated with juvenile-onset Parkinsonism, but these findings do not directly pertain to DNAJC6-AS1 [1][3][5][7]. DNAJC6-AS1 is primarily annotated in transcriptomic datasets as a noncoding RNA gene, and its function, clinical relevance, and druggability remain uncharacterized.

Other names
DNAJC6-AS1AL139294.1
02

Mechanism of action

For antisense RNAs in general, mechanisms may include: Modulation of gene expression via base-pairing and RNA interference; Regulation of mRNA stability, translation or transcription [2][6]. However, DNAJC6-AS1-specific mechanisms have not been documented.

03

Biological functions

Regulation of gene expression (by base pairing with sense mRNA or transcriptional modulation) [2][6]Other biological functions remain speculative
04

Disease associations

No experimental or clinical evidence currently supports an association of DNAJC6-AS1 with any disease, including Parkinson’s disease, cancer, inflammation, etc. Disease association has been described only for the protein-coding DNAJC6 locus [1][5][7].
05

Safety considerations

No known safety concerns, risks, or therapeutic challenges are currently associated with DNAJC6-AS1.
06

Interacting drugs

No known drugs are reported to interact directly with DNAJC6-AS1. Antisense oligonucleotide drugs are conceptually possible for therapeutic modulation of antisense RNAs, but none are reported for this molecule [2].
07

Biomarkers

No published evidence that DNAJC6-AS1 serves as a clinical biomarker for diagnosis, prognosis, or therapeutic monitoring.

Beyond the preview

Go deeper on DNAJC6 antisense RNA 1 (DNAJC6-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNAJC6 antisense RNA 1 (DNAJC6-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call